Ironwood Pharma, Forest Labs (FRX) Report Results from Additional Analyses of Phase 2b Study for Linaclotide in Patients with IBS-C
Tweet Send to a Friend
Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. (NYSE: FRX) today announced results from additional analyses of their Phase 2b study ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
